[go: up one dir, main page]

MX2019009443A - Metodos para tratar la influenza. - Google Patents

Metodos para tratar la influenza.

Info

Publication number
MX2019009443A
MX2019009443A MX2019009443A MX2019009443A MX2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A
Authority
MX
Mexico
Prior art keywords
methods
treat influenza
prevention
treatment
relates
Prior art date
Application number
MX2019009443A
Other languages
English (en)
Other versions
MX387115B (es
Inventor
Ewart Gary
Luscombe Carolyn
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of MX2019009443A publication Critical patent/MX2019009443A/es
Publication of MX387115B publication Critical patent/MX387115B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al tratamiento o prevención de infección por el virus de la influenza. En particular, la presente invención se refiere al uso de N-carbamimidoil-5-(1-metil - 1H-pirazol-4-il)-2-naftamida, o una sal farmacéuticamente aceptable de la misma, en el tratamiento o prevención de infección por el virus de la influenza.
MX2019009443A 2017-02-08 2018-02-07 Métodos para tratar la influenza. MX387115B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (2)

Publication Number Publication Date
MX2019009443A true MX2019009443A (es) 2019-12-16
MX387115B MX387115B (es) 2025-03-19

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009443A MX387115B (es) 2017-02-08 2018-02-07 Métodos para tratar la influenza.

Country Status (13)

Country Link
US (1) US10918623B2 (es)
EP (1) EP3579833B1 (es)
JP (1) JP7019727B2 (es)
KR (1) KR102607599B1 (es)
CN (1) CN110325187B (es)
AU (1) AU2018218179B2 (es)
BR (1) BR112019016316A2 (es)
CA (1) CA3052503A1 (es)
ES (1) ES2910136T3 (es)
MX (1) MX387115B (es)
RU (1) RU2769317C2 (es)
SG (1) SG11201907034PA (es)
WO (1) WO2018145148A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
HRP20220355T1 (hr) 2015-09-16 2022-05-13 Gilead Sciences, Inc. Postupci za liječenje infekcija coronaviridae
TW201836615A (zh) 2017-03-14 2018-10-16 美商基利科學股份有限公司 治療貓冠狀病毒感染之方法
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CN118766947A (zh) 2020-01-27 2024-10-15 吉利德科学公司 用于治疗SARS CoV-2感染的方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
KR20220164784A (ko) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
AU2021281351A1 (en) 2020-05-29 2023-01-19 Gilead Sciences, Inc. Remdesivir treatment methods
PH12022553530A1 (en) 2020-06-24 2024-06-24 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
PL4200301T3 (pl) 2020-08-24 2025-06-09 Gilead Sciences, Inc. Związki fosfolipidowe i ich zastosowania
ES2985995T3 (es) 2020-08-27 2024-11-08 Gilead Sciences Inc Compuestos y métodos para el tratamiento de infecciones víricas
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
EP4346772A1 (en) 2021-05-26 2024-04-10 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4436576A4 (en) * 2021-11-24 2025-09-17 Biotron Ltd METHODS FOR TREATING SARS-CoV-2 INFECTION
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CA3243944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. COMPOUNDS AND METHODS OF TREATMENT FOR VIRAL INFECTIONS
CR20240365A (es) 2022-03-03 2024-10-04 Gilead Sciences Inc Compuestos antivirales y métodos de elaboración y uso de los mismos
CR20240367A (es) 2022-03-03 2024-09-30 Gilead Sciences Inc Compuestos antivirales y métodos de elaboración y uso de los mismos.
AU2023283718A1 (en) 2022-06-06 2024-12-12 Gilead Sciences, Inc. Methods for treatment of viral infections including sars-cov-2
EP4547334A1 (en) 2022-06-29 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4665737A1 (en) 2023-02-16 2025-12-24 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250099476A1 (en) 2023-09-06 2025-03-27 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826770B1 (en) * 2005-06-24 2018-09-12 Biotron Limited Acylguanidine compounds with antiviral activity
CN101827589B (zh) * 2007-08-03 2016-08-17 拜伊特朗有限公司 抗丙型肝炎病毒的组合物及方法
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
BR112017000285A2 (pt) * 2014-07-07 2017-10-31 Prophylaxis LLC métodos de tratamento da profilaxia viral e kits de profilaxia de pré-exposição
CN110870864B (zh) * 2018-08-29 2021-09-24 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Also Published As

Publication number Publication date
JP2020506243A (ja) 2020-02-27
WO2018145148A1 (en) 2018-08-16
EP3579833B1 (en) 2022-01-05
NZ755900A (en) 2025-03-28
CA3052503A1 (en) 2018-08-16
KR20190112051A (ko) 2019-10-02
AU2018218179B2 (en) 2023-05-04
JP7019727B2 (ja) 2022-02-15
EP3579833A1 (en) 2019-12-18
US20200093796A1 (en) 2020-03-26
KR102607599B1 (ko) 2023-11-28
SG11201907034PA (en) 2019-08-27
CN110325187B (zh) 2022-09-30
AU2018218179A1 (en) 2019-08-22
US10918623B2 (en) 2021-02-16
ES2910136T3 (es) 2022-05-11
CN110325187A (zh) 2019-10-11
RU2769317C2 (ru) 2022-03-30
BR112019016316A2 (pt) 2020-03-31
RU2019126746A (ru) 2021-03-09
MX387115B (es) 2025-03-19
EP3579833A4 (en) 2021-01-13
RU2019126746A3 (es) 2021-05-28

Similar Documents

Publication Publication Date Title
MX2019009443A (es) Metodos para tratar la influenza.
DOP2019000201A (es) Compuestos inhibidores del vih
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
AR101740A1 (es) Terapia de combinación y composiciones
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
AR103680A1 (es) Inhibidores selectivos de bace1
MX2018003256A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicacion viral del dengue.
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
BR112018005904A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
BR112018005870A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MX363464B (es) Vacunas contra influenza h5.
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX386783B (es) Compuestos peptidomiméticos que neutralizan el virus influenza.